Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by TheShedCFCon May 30, 2020 9:27pm

110 Views

Post# 31092778

RE:RE:Did The South Korea COVID19 Human Clinical Trial Ever Start?

For sure.......it’s put up or the gig might be up. There are some very interesting posters on this board but only a few that I get excited about when they post something because it’s usually informative. Others (unfortunately most) spew out rhetoric and totally useless garbage. I am a long term holder and continue to believe but need something from AGN that tells me I should stay.

Bullboard Posts

Debt-free cannabis company set for next stage of growth